Acute Hepatotoxicity Caused by Repaglinide
Authors: Daniel N. Nan, José L. Hernández, Marta Fernández-Ayala, Miguel Carrascosa
Journal: Annals of Internal Medicine (2004)

Letters16 November 2004Acute Hepatotoxicity Caused by RepaglinideDaniel N. Nan, MD, José L. Hernández, MD, PhD, Marta Fernández-Ayala, MD, and Miguel Carrascosa, MDDaniel N. Nan, MDFrom University Hospital Marqués de Valdecilla, and Hospital Comarcal de Laredo, 39008 Santander, Spain., José L. Hernández, MD, PhDFrom University Hospital Marqués de Valdecilla, and Hospital Comarcal de Laredo, 39008 Santander, Spain., Marta Fernández-Ayala, MDFrom University Hospital Marqués de Valdecilla, and Hospital Comarcal de Laredo, 39008 Santander, Spain., and Miguel Carrascosa, MDFrom University Hospital Marqués de Valdecilla, and Hospital Comarcal de Laredo, 39008 Santander, Spain.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-141-10-200411160-00024 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: Repaglinide is a short-acting, orally administered drug used to control postprandial hyperglycemia in patients with type 2 diabetes mellitus. Although chemically unrelated to the sulphonylureas, repaglinide acts similarly by stimulating release of insulin from the pancreas β cells. The drug is metabolized in the liver to inactive metabolites, mainly through the CYP3A4 enzyme of the P450 cytochrome system, and is eliminated by the biliary–fecal route (1). Repaglinide is considered a safe agent; adverse events are mild to moderate and are similar to those associated with sulphonylureas. The most frequently reported side effects include hypoglycemia, upper respiratory ...References1. Owens DR. Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes. Eur J Clin Invest. 1999;29 Suppl 2 30-7. [PMID: 10383608] CrossrefMedlineGoogle Scholar2. Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs. 2001;61:1625-60. [PMID: 11577798] CrossrefMedlineGoogle Scholar3. Sherlock S. The spectrum of hepatotoxicity due to drugs. Lancet. 1986;2:440-4. [PMID: 2874423] CrossrefMedlineGoogle Scholar4. Kaplowitz N, Aw TY, Simon FR, Stolz A. Drug-induced hepatotoxicity. Ann Intern Med. 1986;104:826-39. [PMID: 3518564] LinkGoogle Scholar5. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45. [PMID: 7249508] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Daniel N. Nan, MD; José L. Hernández, MD, PhD; Marta Fernández-Ayala, MD; Miguel Carrascosa, MDAffiliations: From University Hospital Marqués de Valdecilla, and Hospital Comarcal de Laredo, 39008 Santander, Spain. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAn Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the HepatologistDiabetestherapie bei fortgeschrittenen Lebererkrankungen und LeberzirrhoseManagement of diabetes mellitus in patients with cirrhosis: An overview and joint statementDrug-Induced Liver InjuryDrugs and ToxinsMeglitinidesPharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver diseaseA review of the efficacy and safety of oral antidiabetic drugsHepatotoxicity of Cardiovascular and Antidiabetic DrugsHepatic injury due to drugs, herbal compounds, chemicals and toxinsDrug-Induced Liver InjuryDrug‐Induced Liver DiseaseINSULINS AND OTHER HYPOGLYCEMIC DRUGS42 Insulin, other hypoglycemic drugs, and glucagonDrug-Induced Liver InjuryCurrent awareness: Pharmacoepidemiology and drug safetyDrug-induced liver disease 2004Heparin-Induced Thrombocytopenia; Hepatotoxicity with Newer Diabetes Agent; Acute Myocardial Infarction Associated with Albuterol; Olanzapine-Induced Hyperglycemic Hyperosmolar Nonketotic Coma; Paronychia and Skin Hyperpigmentation Due to Gefitinib; Selective Serotonin Reuptake Inhibitor-Induced Enuresis; Do Antidepressants Confer a Decreased Risk for Myocardial Infarction?; Recent Adverse Event Reviews; An Online Interview Discussing the Reduction of ADRs 16 November 2004Volume 141, Issue 10Page: 823KeywordsAdverse reactionsBilirubinDrugsEosinophiliaHypersensitivityLiverLiver function testsType 2 diabetesUltrasound imagingVomiting ePublished: 16 November 2004 Issue Published: 16 November 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...